Adenylyl cyclase 1 as a Therapy Target for Ethanol-Induced Neuroplastic Deficits

腺苷酸环化酶 1 作为乙醇引起的神经塑性缺陷的治疗靶点

• 批准号: 8985380
• 负责人: Kelly Bosse
• 金额: --
• 依托单位: JOHN D DINGELL VA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-11-01 至 2020-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8985380
• 关键词: Acute; Address; Adenylate Cyclase; Alcohol consumption; Alcohol dependence; Alcohols; Attenuated; Award; Behavior; Biological Models; Biological Process; Brain; Brain region; Calcium; Calmodulin; Chronic; Clinical; Consumption; Corpus striatum structure; Cyclic AMP-Dependent Protein Kinases; Data; Development; Dorsal; Electrophysiology (science); Emotional; Enzymes; Ethanol; Face; Functional disorder; Gene Deletion; Glutamates; Hippocampus (Brain); Human; Individual; Intake; Intervention; Lead; Medial; Mediating; Mentors; Military Personnel; Mission; Modification; Molecular; Morphology; Motivation; Motor Activity; Mus; N-Methyl-D-Aspartate Receptors; Neuronal Plasticity; Neurons; Pathway interactions; Patient Care; Phosphoric Monoester Hydrolases; Phosphorylation; Phosphotransferases; Physiological; Population; Productivity; Protein Isoforms; Proteins; Published Comment; Regulation; Rehabilitation therapy; Research; Rewards; Risk; Role; Sedation procedure; Signal Pathway; Signal Transduction; Site; Specificity; Surface; Synapses; Techniques; Therapeutic; Thinking; Training; Tyrosine Phosphorylation; Up-Regulation; Vertebral column; Veterans; Viral; adenylyl cyclase 1; alcohol exposure; alcohol response; alcohol use disorder; alcoholism pharmacotherapy; behavioral response; drinking behavior; effective therapy; health administration; improved; inhibitor/antagonist; neuroadaptation; novel; novel therapeutics; postsynaptic; preference; problem drinker; programs; receptor function; recombinase; response; signal processing; targeted treatment; trafficking; transmission process

 DESCRIPTION: The application is a third submission of a CDA-2 that has been reviewed by a VA review panel twice before. The previous application was reviewed favorably with the majority of the negative comments being related to the mentoring program. In addition, there were some small comments related to the specificity of the effect and the region of the brain to be studied and the use of pharmacological inhibitors. The author has responded very strongly scientifically by adding figures 8 and 14 to the revised proposal where she shows that ethanol intake is significantly decreased in the AC1 inhibitor group. I think this is a thorough response to the scientific portion. Regarding mentoring, the applicant has provided more information regarding the productivity, seniority and the training to be provided by Dr. Conti. In my opinion, this response was less convincing. My overall level of enthusiasm is only moderate.

 描述： 该申请是 CDA-2 的第三次提交，之前已经过 VA 审核小组两次审核，之前的申请获得了好评，其中大部分负面评论与指导计划有关。此外，还有一些小的评论。与效果的特异性和要研究的大脑区域以及 作者在修订后的提案中添加了图 8 和 14，对此做出了非常强烈的科学回应，其中她表明 AC1 抑制剂组的乙醇摄入量显着减少，我认为这是对科学部分的彻底回应。在我看来，这个回答不太令人信服。我的总体热情程度适中。